Folate-targeted chemotherapy

Advanced Drug Delivery Reviews

Volumn 56, Issue 8, 2004, Pages 1127-1141

  Leamon, Christopher P ^a   Reddy, Joseph A ^a  

^a Endocyte Inc   (United States)

Author keywords

Cancer therapy; Endocytosis; Folate receptor; Pteroate; Targeted drug delivery

Indexed keywords

ANTIGENS; CELLS; DNA; DRUG DOSAGE; MOLECULAR WEIGHT; MOLECULES; RADIOACTIVE ELEMENTS; TUMORS;

ENDOCYTIC MECHANISM; FOLATE RECEPTOR (FR); FOLATE-DRUG; TUMOR-ASSOCIATED ANTIGEN;

CHEMOTHERAPY;

ANTINEOPLASTIC AGENT; CYSTEINE; EC 16; EC 72; FLUOROURACIL; FOLATE 5 FLUORO 2' DEOXYURIDINE 5' O MONOPHOSPHATE CONJUGATE; FOLATE GAMMA CYSTEINE; FOLATE GAMMA CYSTEINE MITOMYCIN C CONJUGATE; FOLATE GAMMA CYSTEINE TAXOL; FOLATE MACROGOL PTEROATE CONJUGATE; FOLATE METHYLDITHIOMAYTANSINOID; FOLATE RECEPTOR; FOLIC ACID; FOLIC ACID DERIVATIVE; MAYTANSINE; MEMBRANE RECEPTOR; MITOMYCIN C; MYELOTARG; PACLITAXEL; PTEROATE NITROHETEROCYCLIC BIS(HALOETHYL)PHOSPHORAMIDITE CONJUGATE; PTEROATE TAXOL CONJUGATE; UNCLASSIFIED DRUG;

BINDING AFFINITY; CANCER CHEMOTHERAPY; CONCENTRATION RESPONSE; DRUG BINDING; DRUG CONJUGATION; DRUG DELIVERY SYSTEM; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SCREENING; DRUG TARGETING; ENDOCYTOSIS; HUMAN; MOLECULAR WEIGHT; NONHUMAN; PRIORITY JOURNAL; REVIEW;

EID: 1942503286     PISSN: 0169409X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.addr.2004.01.008     Document Type: Article

References (70)

1. Kamen B.A., Capdevila A. Receptor-mediated folate accumulation is regulated by the cellular folate content. Proc. Natl. Acad. Sci. U. S. A. 83:1986;5983-5987.
2. Leamon C.P., Low P.S. Delivery of macromolecules into living cells: a method that exploits folate receptor endocytosis. Proc. Natl. Acad. Sci. U. S. A. 88:1991;5572-5576.
3. Leamon C.P., Low P.S. Membrane folate-binding proteins are responsible for folate-protein conjugate endocytosis into cultured cells. Biochem. J. 291:1993;855-860.
4. Lee R.J., Wang S., Low P.S. Measurement of endosome pH following folate receptor-mediated endocytosis. Biochim. Biophys. Acta. 1312:1996;237-242.
5. 67Ga-deferoxamine-folate, a potential radiopharmaceutical for tumor imaging. Bioconjug. Chem. 7:1996;56-62.
6. Mathias C.J., Wang S., Lee R.J., Waters D.J., Low P.S., Green M.A. Tumor-selective radiopharmaceutical targeting via receptor-mediated endocytosis of Gallium-67-deferoxamine-folate. J. Nucl. Med. 37:1996;1003-1008.
7. Mathias C.J., Wang S., Waters D.J., Turek J.J., Low P.S., Green M.A. Indium-111-DTPA-folate as a potential folate-receptor-targeted radiopharmaceutical. J. Nucl. Med. 39:1998;1579-1585.
8. 99mTc-Ethylenedicysteine-folate: a new tumor imaging agent. Synthesis, labeling and evaluation in animals. Cancer Biother. Radiopharm. 13:1998;427-435.
9. 99mTc-HYNIC-folate: a novel receptor-based targeted radiopharmaceutical for tumor imaging. J. Nucl. Med. 40:1999;1563-1569.
10. 99mTc-OXA-Folate show uptake of both isomers in folate-receptor (+) KB cell lines. Proc. 47th Annu. Meet. Soc. Nucl. Med. 41:2000;119P.
11. 99mTc-based radiopharmaceutical. Bioconjug. Chem. 13(6):2002;1200-1210.
12. Konda S.D., Aref M., Brechbiel M., Wiener E.C. Development of a tumor-targeting MR contrast agent using the high-affinity folate receptor. Invest. Radiol. 35:2000;50-57.
13. Ladino C.A., Chari R.V.J., Bourret L.A., Kedersha N.L., Goldmacher V.S. Folate-maytansinoids: target-selective drugs of low molecular weight. Int. J. Cancer. 73:1997;859-864.
14. Lee J.W., Lu J.Y., Low P.S., Fuchs P.L. Synthesis and evaluation of taxol-folic acid conjugates as targeted antineoplastics(dagger). Bioorg. Med. Chem. 10:2002;2397-2414.
15. Steinberg G., Borch R.F. Synthesis and evaluation of pteroic acid-conjugated nitroheterocyclic phosphoramidates as folate receptor-targeted alkylating agents. J. Med. Chem. 44:2001;69-73.
16. Aronov O., Horowitz A.T., Gabizon A., Gibson D. Folate-targeted PEG as a potential carrier for Carboplatin analogs. Synthesis and in vitro studies. Bioconjug. Chem. 14:2003;563-574.
17. Liu J., Kolar C., Lawson T.A., Gmeiner W.H. Targeted drug delivery to chemoresistant cells: folic acid derivatization of FdUMP[10] enhances cytotoxicity toward 5-FU-resistant human colorectal tumor cells. J. Org. Chem. 66:2001;5655-5663.
18. Citro G., Szczylik C., Ginobbi P., Zupi G., Calabretta B. Inhibition of leukaemia cell proliferation by folic acid-polylysine-mediated introduction of c-myb antisense oligodeoxynucleotides into HL-60 cells. Br. J. Cancer. 69:1994;463-467.
19. Li S., Huang L. Targeted delivery of antisense oligodeoxynucleotides by LPDII. J. Liposome Res. 7:1997;63-75.
20. Li S., Huang L. Targeted delivery of antisense oligodeoxynucleotides formulated in a novel lipidic vector. J. Liposome Res. 8:1998;239-250.
21. Li S., Deshmukh H.M., Huang L. Folate-mediated targeting of antisense oligonucleotides to ovarian cancer cells. Pharm. Res. 15:1998;1540-1545.
22. Leopold L.H., Shore S.K., Newkirk T.A., Reddy R.M., Reddy E.P. Multi-unit ribozyme-mediated cleavage of bcr-abl mRNA in myeloid leukemias. Blood. 85:1995;2162-2170.
23. Ward C.M., Acheson N., Seymour L.M. Folic acid targeting of protein conjugates into ascites tumor cells from ovarian cancer patients. J. Drug Target. 8:2000;119-123.
24. Lu J.Y., Lowe D.A., Kennedy M.D., Low P.S. Folate-targeted enzyme prodrug cancer therapy utilizing penicillin-V amidase and a doxorubicin prodrug. J. Drug Target. 7:1999;43-53.
25. Leamon C.P., Low P.S. Cytotoxicity of momordin-folate conjugates in cultured human cells. J. Biol. Chem. 267:1992;24966-24971.
26. Leamon C.P., Low P.S. Selective targeting of malignant cells with cytotoxin-folate conjugates. J. Drug Target. 2:1994;101-112.
27. Kranz D.M., Patrick T.A., Brigle K.E., Spinella M.J., Roy E.J. Conjugates of folate and anti-T-cell-receptor antibodies specifically target folate-receptor-positive tumor cells for lysis. Proc. Natl. Acad. Sci. U. S. A. 92:1995;9057-9061.
28. Cho B.K., Roy E.J., Patrick T.A., Kranz D.M. Single-chain Fv/folate conjugates mediate efficient lysis of folate-receptor-positive tumor cells. Bioconjug. Chem. 8:1997;338-346.
29. Kranz D.M., Manning T.C., Rund L.A., Cho B.K., Gruber M.M., Roy E.J. Targeting tumor cells with bispecific antibodies and T cells. J. Control. Release. 53:1998;77-84.
30. Rund L.A., Cho B.K., Manning T.C., Holler P.D., Roy E.J., Kranz D.M. Bispecific agents target endogenous murine T cells against human tumor xenografts. Int. J. Cancer. 83:1999;141-149.
31. Lee R.J., Low P.S. Delivery of liposomes into cultured KB cells via folate receptor-mediated endocytosis. J. Biol. Chem. 269:1994;3198-3204.
32. Lee R.J., Low P.S. Folate-mediated tumor cell targeting of liposome-entrapped doxorubicin in vitro. Biochim. Biophys. Acta. 1233:1995;134-144.
33. Vogel K., Wang S., Lee R.J., Chmielewski J., Low P.S. Peptide-mediated release of folate-targeted liposome contents from endosomal compartments. J. Am. Chem. Soc. 118:1996;1581-1586.
34. Rui Y., Wang S., Low P.S., Thompson D.H. Diplasmenylcholine-folate liposomes: an efficient vehicle for intracellular drug delivery. J. Am. Chem. Soc. 120:1998;11213-11218.
35. Gabizon A., Horowitz A.T., Goren D., Tzemach D., Mandelbaum-Shavit F., Qazen M.M., Zalipsky S. Targeting folate receptor with folate linked to extremities of poly(ethylene glycol)-grafted liposomes: in vitro studies. Bioconjug. Chem. 10:1999;289-298.
36. Zhang Y., Kohler N., Zhang M. Surface modification of superparamagnetic magnetite nanoparticles and their intracellular uptake. Biomaterials. 23:2002;1553-1561.
37. Oyewumi M.O., Mumper R.J. Engineering tumor-targeted gadolinium hexanedione nanoparticles for potential application in neutron capture therapy. Bioconjug. Chem. 13:2002;1328-1335.
38. Oyewumi M.O., Mumper R.J. Influence of formulation parameters on gadolinium entrapment and tumor cell uptake using folate-coated nanoparticles. Int. J. Pharm. 251:2003;85-97.
39. Gottschalk S., Cristiano R.J., Smith L.C., Woo S.L.C. Folate receptor mediated DNA delivery into tumor cells: potosomal disruption results in enhanced gene expression. Gene Ther. 1:1994;185-191.
40. Mislick K.A., Baldeschwieler J.D., Kayyem J.F., Meade T.J. Transfection of folate-polylysine DNA complexes: evidence for lysosomal delivery. Bioconjug. Chem. 6:1995;512-515.
41. Douglas J.T., Rogers B.E., Rosenfeld M.E., Michael S.I., Feng M., Curiel D.T. Targeted gene delivery by tropism-modified adenoviral vectors. Nat. Biotechnol. 14:1996;1574-1578.
42. Leamon C.P., Weigl D., Hendren R.W. Folate copolymer-mediated transfection of cultured cells. Bioconjug. Chem. 10:1999;947-957.
43. Guo W., Lee R.J. Receptor-targeted gene delivery via folate-conjugated polyethylenimine. AAPS PharmSci. 1(4):1999;E19.
44. Reddy J.A., Dean D., Kennedy M.D., Low P.S. Optimization of folate-conjugated liposomal vectors for folate receptor-mediated gene therapy. J. Pharm. Sci. 88:1999;1112-1118.
45. Reddy J.A., Low P.S. Enhanced folate receptor mediated gene therapy using a novel pH-senistive lipid formulation. J. Control. Release. 64:2000;27-37.
46. Reddy J.A., Abburi C., Hofland H., Howard S.J., Vlahov I., Wils P., Leamon C.P. Folate-targeted, cationic liposome-mediated gene transfer into disseminated peritoneal tumors. Gene Ther. 9:2002;1542-1550.
47. Hofland H.E., Masson C., Iginla S., Osetinsky I., Reddy J.A., Leamon C.P., Scherman D., Bessodes M., Wils P. Folate-targeted gene transfer in vivo. Molec. Ther. 5:2002;739-744.
48. Leamon C.P., DePrince R.B., Hendren R.W. Folate-mediated drug delivery: effect of alternative conjugation chemistry. J. Drug Target. 7:1999;157-169.
49. Leamon C.P., Cooper S.R., Hardee G.E. Folate-liposome-mediated antisense oligodeoxynucleotide targeting to cancer cells: evaluation in vitro and in vivo. Bioconjug. Chem. 14:2003;738-747.
50. Feener E.P., Shen W.C., Ryser H.J.P. Cleavage of disulfide bonds in endocytosed macromolecules. J. Biol. Chem. 265:1990;18780-18785.
51. McIntyre G.D., Scott C.F., Ritz J., Blattler W.A., Lambert J.M. Preparation and characterization of interleukin-2-gelonin conjugates made using different cross-linking reagents. Bioconjug. Chem. 5:1994;88-97.
52. Leamon C.P., Pastan I., Low P.S. Cytotoxicity of folate-pseudomonas exotoxin conjugates toward tumor cells. J. Biol. Chem. 268:1993;24847-24854.
53. Liu C., Tadayoni B.M., Bourret L.A., Mattocks K.M., Derr S.M., Widdison W.C., Kedersha N.L., Ariniello P.D., Goldmacher V.S., Lambert J.M., Blattler W.A., Chari R.V. Eradication of large colon tumor xenografts by targeted delivery of maytansinoids. Proc. Natl. Acad. Sci. U. S. A. 93:1996;8618-8623.
54. Neville D.M., Srinivasachar K., Stone R., Scharff J. Enhancement of immunotoxin efficacy by acid-cleavable cross-linking agents utilizing diphtheria toxin and toxin mutants. J. Biol. Chem. 264:1989;14653-14661.
55. Hamann P.R., Hinman L.M., Beyer C.F., Lindh D., Upeslacis J., Flowers D.A., Bernstein I. An anti-CD33 antibody-calicheamicin conjugate for treatment of acute myeloid leukemia. Choice of linker. Bioconjug. Chem. 13:2002;40-46.
56. Hamann P.R., Hinman L.M., Hollander I., Beyer C.F., Lindh D., Holcomb R., Hallett W., Tsou H.R., Upeslacis J., Shochat D., Mountain A., Flowers D.A., Bernstein I. Gemtuzumab ozogamicin, a potent and selective anti-CD33 antibody-calicheamicin conjugate for treatment of acute myeloid leukemia. Bioconjug. Chem. 13:2002;47-58.
57. Westerhof G.R., Schornagel J.H., Kathmann I., Jackman A.L., Rosowsky A., Forsch R.A., Hynes J.B., Boyle F.T., Peters G.J., Pinedo H.M., Jansen G. Carrier- and receptor-mediated transport of folate antagonists targeting folate-dependent enzymes: correlates of molecular structure and biological activity. Mol. Pharmacol. 48:1995;459-471.
58. McHugh M., Cheng Y.C. Demonstration of a high affinity folate binder in human cell membranes and its characterization in cultured human KB cells. J. Biol. Chem. 254:1979;11312-11318.
59. Boyd M.R. The NCI in vitro anticancer drug discovery screen. Teicher B. Anticancer Drug Development Guide: Preclinical Screening, Clinical Trials, and Approval. 1997;23-42 Humana Press, Totowa.
60. Marsh M., Helenius A. Adsorptive endocytosis of Semliki Forest virus. J. Mol. Biol. 142:1980;439-454.
61. Rothberg K.G., Ying Y., Kolhouse J.F., Kamen B.A., Anderson R.G.W. The glycophospholipid-linked folate receptor internalizes folate without entering the clathrin-coated pit endocytic pathway. J. Biol. Chem. 110:1990;637-649.
62. 99mTc labeling of highly potent small peptides. Bioconjug. Chem. 8:1997;621-636.
63. Zettner A., Duly P.E. The weak binding reaction between folate and human serum proteins. Ann. Clin. Lab. Sci. 8:1978;57-63.
64. Birn H., Nielsen S., Christensen E.I. Internalization and apical-to-basolateral transport of folate in rat kidney proximal tubule. Am. J. Physiol. 272:1997;F70-F78.
65. Lawrence V.A. Demographic analysis of serum folate and folate-binding capacity in hospitalized patients. Acta Haematol. 69:1983;289-293.
66. Leamon C.P. Folate-targeted chemotherapy: in vitro and in vivo activity of EC72. Proc. Am. Assoc. Cancer Res. 44:2003;600. (Abstract no. 2627).
67. Birn H., Selhub J., Christensen E.I. Internalization and intracellular transport of folate-binding protein in rat kidney proximal tubule. Am. J. Physiol. 264:1993;C302-C310.
68. Weitman S.D., Lark R.H., Coney L.R., Fort D.W., Frasca V., Zurawski V.R., Kamen B.A. Distribution of the folate receptor GP38 in normal and malignant cell lines and tissues. Cancer Res. 52:1992;3396-3401.
69. Morshed K.M., Ross D.M., McMartin K.E. Folate transport proteins mediate the bidirectional transport of 5-methyltetrahydrofolate in cultured human proximal tubule cells. J. Nutr. 127:1997;1137-1147.
70. Turek J.J., Leamon C.P., Low P.S. Endocytosis of folate-protein conjugates: ultrastructural localization in KB cells. J. Cell. Sci. 106:1993;423-430.